Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. Journal Articles Refereed uri icon

Overview

Time

Date/time value

  • 2019

Identity

Digital Object Identifier (DOI)

  • 10.1002/hsr2.115

Additional Document Info

Parent Title

  • Health Sci Rep

Volume

  • 2

Issue

  • 3

Publisher

  • publisher